FibroGen (NASDAQ:FGEN) Earns Hold Rating from Analysts at StockNews.com
Research analysts at StockNews.com started coverage on shares of FibroGen (NASDAQ:FGEN – Get Free Report) in a report released on Tuesday. The firm set a “hold” rating on the biopharmaceutical company’s stock. Several other analysts have also recently weighed in on FGEN. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on […]
Research analysts at StockNews.com started coverage on shares of FibroGen (NASDAQ:FGEN – Get Free Report) in a report released on Tuesday. The firm set a “hold” rating on the biopharmaceutical company’s stock. Several other analysts have also recently weighed in on FGEN. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on […]